Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(5 sites)

United States

University of Illinois Cancer Center, Chicago, Illinois

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Wisconsin, Madison, Wisconsin